SYNGAP1 Legislative Advocacy

Buchanan, Ingersoll, and Rooney PC, on behalf of the SYNGAP1 Foundation, will provide pro bono services to develop and execute a government relations strategy aligning SYNGAP1's agenda with the current environment in Washington, D.C.

Lobby Registration

REAUTHORIZATION OF THE RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM

HON. MICHAEL T. McCAUL

of Texas in the House of Representatives

Thursday, July 14, 2016

This program is a crucial incentive--in addition to the Orphan Drug Act--for drug manufacturers to invest significantly in developing therapies for rare pediatric diseases, including pediatric cancers and lysosomal storage disorders.

Federal Legislative Letters of Support

SYNGAP1 Legislative Advocacy

Buchanan, Ingersoll, and Rooney PC, on behalf of the SYNGAP1 Foundation, will provide pro bono services to develop and execute a government relations strategy aligning SYNGAP1's agenda with the current environment in Washington, D.C.

REAUTHORIZATION OF THE RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM

Federal Legislative Letters of Support

All Advocacy Efforts Will Be Listed Shortly